EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition

Maozhong Yao, Keyan Zhong, Xinbin Zheng, Zhaoxin Yang, Chunying Li, Yong Gu, Zhanjuan Chen iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Maozhong Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Affiliated Chinese Medicine Hospital of Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, Hainan, Chi…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Epithelial-Mesenchymal Transition, Lactate Dehydrogenase 5, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Natural Science Foundation of China, TCM Geriatrics Construction Project, Key Discipline of National Administration of TCM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial‐to‐mesenchymal transition (EndMT) induced by dysfunctional pulmonary artery endothelial cells (PAECs) is regarded as an initiating and pivotal factor in pulmonary hypertension (PH). This study focuses on identifying a novel therapeutic target for regulating EndMT in PH. A comprehensive analysis of 2 hypoxic PAECs datasets yielded 310 overlapping upregulated and 229 downregulated differentially expressed genes (DEGs). These upregulated DEGs were primarily enriched in HIF‐1 signalling pathway and glycolysis/gluconeogenesis, while downregulated only in spliceosome, as indicated by KEGG. Through PPI network analysis and the application of MCC algorithms, 5 hub genes were identified among these upregulated DEGs: GAPDH, LDHA, ALDOA, PFKL, and PFKP. Their enrichment in the 2 aforementioned pathways was confirmed by cross‐pathway DEGs analysis and ClueGo. Among the hub genes, LDHA was chosen as the key gene based upon expression and correlation analysis of the validation set from PH patients. Subsequent GSEA also revealed the enrichment of LDHA in these 2 pathways. Additionally, the increased expression of LDHA protein in tissues and cells was confirmed, and the elevated enzymatic activity of LDHA in clinical serum samples was also verified. From 2 online databases, 4 LDHA inhibitors were filtered out, and the stable binding between the inhibitors and the LDHA protein was confirmed through molecular docking and molecular dynamics simulation. Finally, the experimental results indicated that one of the inhibitors FX11 reversed EndMT by inhibiting the lactate‐SNAI1 axis, thereby alleviating hypoxia‐induced PH. The potential of LDHA as a therapeutic target for PH by modulating EndMT was proposed in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryEpithelial-Mesenchymal TransitionLactate Dehydrogenase 5L-Lactate DehydrogenaseHumansEndothelial CellsPulmonary ArteryProtein Interaction MapsGene Regulatory NetworksSignal TransductionGene Expression ProfilingGene Expression RegulationMolecular Docking Simulation

Stichwörter der Autor:innen

FX11bioinformatics analysisendothelial‐to‐mesenchymal transitionlactate dehydrogenase Apulmonary hypertensiontherapeutic target

Substanzen

Lactate Dehydrogenase 5LDHA protein, humanL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Clinical Research Center, Affiliated Chinese Medicine Hospital of Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, Hainan, China.
  • Clinical Research Center, Hainan Hospital, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Haikou, Hainan, China.
  • Hainan Clinical Center for Encephalopathy of Chinese Medicine, Haikou, Hainan, China.
  • Hainan Clinical Research Center for Preventive Treatment of Diseases, Haikou, Hainan, China.
  • Clinical Skills Experimental Teaching Center, Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, Hainan, China.
  • Research Center for Drug Safety Evaluation of Hainan Province, Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, Hainan, China.

ORCID-Profile: Zhanjuan Chen

Förderung

  • Hainan Provincial Natural Science Foundation of China
  • TCM Geriatrics Construction Project, Key Discipline of National Administration of TCM

Zitieren

APA

Yao, M., Zhong, K., Zheng, X., Yang, Z., Li, C., Gu, Y., & Chen, Z. (2025). Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70692

Vancouver

Yao M, Zhong K, Zheng X, Yang Z, Li C, Gu Y, et al. Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70692

BibTeX
@article{Yao2025,
  author = {Yao, Maozhong and Zhong, Keyan and Zheng, Xinbin and Yang, Zhaoxin and Li, Chunying and Gu, Yong and Chen, Zhanjuan},
  title = {Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70692}
}
Kostenlos starten →